LIfT’s CEO challenges out dated thinking that therapies focused on T-Cells alone are enough to achieve complete remission in most solid tumours
During a presentation at the Biotech Showcase, our CEO, Alex Blyth challenged the current view that T-cells can do it all, highlighting...
Feb 22, 2024
LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors
London, 21st December 2023 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company bringing to market a...
Dec 21, 2023
LIfT successfully produces CAR-IMANs to further enhance alpha neutrophil cancer killing
LIfT BioSciences reports a substantial increase in cancer killing with the addition of a HER2 targeting CAR to its IMAN cell therapy...
Aug 2, 2023
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies from iPSCs
- LIfT announces successful production of first-in-class neutrophil based cell therapy from iPSCs - Use of iPSCs will enable production...
Jul 6, 2023
LIfT BioSciences announces data demonstrating potent killing of pancreatic cancer tumouroids
IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model IMAN is the world’s first...
May 4, 2023
